Single User
£3188
PDF
40 pages

Dyslipidaemia (Familial Type) Forecast in 8 Major Markets 2016-2026


Dyslipidaemia is defined as individuals with elevated triglycerides, low density lipoprotein or total cholesterol, or with lowered levels of high density lipoprotein. Many patients meet the requirements of Dyslipidaemia on more than one factor.

Dyslipidaemia can be divided into two forms: familial (primary) or acquired (secondary). Primary causes are single or multiple gene mutations and secondary causes are mainly a result of a sedentary lifestyle, with diets that consist largely of saturated fats, cholesterol and trans-fats.

This report provides the current prevalent population for Dyslipidaemia, with primary focus on the familial/primary type, across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Familial Dyslipidaemia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Dyslipidaemia include:

  • Diabetes & metabolic syndrome
  • Paresthesias
  • Coronary artery disease
  • Peripheral arterial disease
  • Aortic stenosis (familial)
  • Xanthomas (familial)

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global Dyslipidaemia’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Dyslipidaemia and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Dyslipidaemia’s prevalent population.
  • Identify sub-populations within Dyslipidaemia which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Dyslipidaemia patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
    • Additional data available on request
  • Top-Line Prevalence for Dyslipidaemia
  • Secondary vs. Primary Dyslipidaemia
    • Type of Dyslipidaemia in Patients
    • Associated Conditions of Familial Dyslipidaemia
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
  List of Figures
  • Prevalence of familial dyslipidaemia by Fredrickson classification type
List of Tables
  • Fredrickson Classification of Familial Hyperlipidaemias
  • Prevalence of Dyslipidaemia, total (000s)
  • Prevalence of Dyslipidaemia, males (000s)
  • Prevalence of Dyslipidaemia, females (000s)
  • Prevalence of type of Dyslipidaemia, total (000s)
  • Fredrickson phenotype in Familial Dyslipidaemia patients, total (000s)
  • Inheritance pattern of Familial Dyslipidaemia, total (000s)
  • Prevalence of xanthoma in Familial Dyslipidaemia, total (000s)
  • Prevalence of Type 2 Diabetes in Familial Dyslipidaemia, total (000s)
  • Prevalence of hypertension in Familial Dyslipidaemia, total (000s)
  • Prevalence of mild cognitive impairment in Familial Dyslipidaemia, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
  • USA Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
  • France Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
  • France Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
  • Germany Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
  • Germany Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
  • Italy Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
  • Italy Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
  • Spain Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
  • Spain Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
  • Japan Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
  • Japan Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
Brazil, France, Germany, Italy, Japan, Spain, United Kingdom, United States of America